Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab (Q34694813)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab |
scientific article |
Statements
1 reference
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab (English)
1 reference
Tanios Bekaii-Saab
1 reference
Shubham Pant
1 reference
Ludmila K Martin
1 reference
Susan Geyer
1 reference
Lai Wei
1 reference
Katherine Van Loon
1 reference
Nili Sommovilla
1 reference
Mark Zalupski
1 reference
Renuka Iyer
1 reference
David Fogelman
1 reference
Andrew H Ko
1 reference
13 March 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference